In this episode, host Shikha Jain, MD, speaks with Jorge García, PharmD, about the economic benefits of biosimilars, the unique perspective pharmacists can bring to cancer care costs and more.
• Welcome to another exciting episode of Oncology Overdrive :14
• About García :23
• The interview 2:44
• How did you enter the world of pharmacy? What was your journey into this field? 3:11
• Can you tell us about what biosimilars are, and how you found yourself in this space? 5:09
• What do you think is the next step for biosimilars? 6:34
• What types of diseases specifically are biosimilars the most exciting for? … What are diseases that biosimilars have the highest impact in? 8:09
• What is Act4Biosimilars, and what do they do? 12:05
• How did you get involved with Act4Biosimilars? 13:04
• Can you expand on what Act4Biosimilars is doing to address inequities and disparities in health care? Is there a way to get biosimilars into the hands of more people who really need it? 14:55
• How do you see the impact of these initiatives and interventions are going to be over the next few years? 17:14
• How do you suggest people who are interested in getting involved in this type of work find this path? 19:31
• Jain and García on his unique perspective of being a pharmacist and having an MBA and understanding cost of care 24:22
• If you had a crystal ball, and you could see five or ten years from now, what do you hope will have changed in the biosimilar news space? 27:13
• If someone could only listen to the two minutes of this episode, what would you want them to take away? 30:36
• How to contact García 31:27
• Thanks for listening 32:32
Jorge García, PharmD, MS, MHA, MBA, FACHE is the assistant vice president at Baptist Health South Florida, where he is responsible for oncology pharmacy services, non-oncology infusion pharmacy services, and sterile compounding quality.
We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. García can be reached via LinkedIn.
Disclosures: García and Jain report no relevant financial disclosures.
